SPRY | ARS Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	13.15 - 13.87
52 Week Range	4.65 - 18.51
Beta	2.13
Implied Volatility	58.12%
IV Rank	-1.79%
Day's Volume	1,118,377
Average Volume	1,102,280
Shares Outstanding	97,185,500
Market Cap	1,316,863,525
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-04

Valuation
Profitability
Growth
Health
P/E Ratio	-27.10
Forward P/E Ratio	N/A
EPS	-0.50
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	23
Country	USA
Website	SPRY

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

SPRY's peers: ZURA, ANNX, ICVX, INAB, WVE, PALI, CFRX, ALLR, CNSP, WINT, IMMX, HEPA, FRLN, AVRO, CGTX, TFFP, TCRX, CUE, DRMA

*Chart delayed

Analyzing fundamentals for SPRY we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see SPRY Fundamentals page.

Watching at SPRY technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on SPRY Technicals page.